Evidence map›Paper›PMID 39944766›Full record

ReviewFrontiers in cellular neuroscience2025

The role of neurotrophic factors in retinal ganglion cell resiliency.

Alan K Abraham, Michael Telias

Abstract readReview
In one paragraph

Review in Frontiers in cellular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alan K AbrahamDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, United States.
Michael TeliasFlaum Eye Institute, University of Rochester Medical Center, Rochester, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many retinal diseases are characterized by direct or indirect retinal ganglion cell (RGC) neurodegeneration. In glaucoma and optic nerve neuropathies, RGCs are the primary affected cells, whereas in photoreceptor dystrophies, RGC loss is secondary to the death of rods and cones. The death of RGCs in either case will irreversibly cause loss of vision, as RGCs are the sole output neurons of the retina. RGC neurodegeneration affects certain neurons preferentially, resulting in subpopulations of resilient and susceptible cells. Neurotrophins (NTs) are known to mediate neuronal survival through the downstream activation of various anti-apoptotic pathways. In this review, we summarize the current methods of RGC identification and quantification in animal models of direct or indirect neurodegeneration, and describe the advantages and disadvantages associated with these techniques. Using these techniques, multiple studies have uncovered the potential role of NTs in protecting RGCs during direct neurodegeneration, with BDNF and NGF delivery promoting RGC survival in models of experimental glaucoma. Many fewer studies have addressed similar questions in retinal diseases where RGC loss is secondary to photoreceptor degeneration, yielding conflicting results. Our analysis suggests that these seemingly contradictory results can be explained by the varying onset and geographic distribution of photoreceptor death.

Indexed as

brain derived neurotrophic factorglaucomaneurotrophinretinal ganglion cellretinitis pigmentosatropomyosin receptor kinase

Identifiers

PMID39944766
PMCPMC11814206

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.